Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 82

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 82
---
1.175 per share. The January 2025 Placement Agent Warrants are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date.

November 2024 Financing

On November 22, 2024, we entered into securities purchase agreements, or the November 2024 Purchase Agreements, with certain institutional and accredited investors, or the November 2024 Purchasers. The November 2024 Purchase Agreements provide for the sale and issuance by us of an aggregate of: (i) 1,817,017 shares of our common stock in a registered direct offering and (ii) warrants to purchase 1,817,017 shares of common stock in a private placement, or the November 2024 Warrants. The shares and November 2024 Warrants were sold on a combined basis for consideration of $1.175 for one share and a November 2024 Warrant. The exercise price of the November 2024 Warrants is $1.05 per share. One of the November 2024 Purchasers was our Chief Executive Officer, who purchased 42,553 shares and November 2024 Warrants to purchase 42,553 shares, or the Affiliate Securities, at the same price and upon the same terms as the other November 2024 Purchasers.

The November 2024 Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The November 2024 Warrants contain standard adjustments to the exercise price including for stock splits, stock dividends and reorganizations. In lieu of making the cash payment otherwise contemplated to be made upon exercise in payment of the aggregate exercise price, the holder may, in the event the shares underlying the November 2024 Warrants are not registered under the Securities Act, elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the November 2024 Warrants. Under the terms of the November 2024 Warrants, a holder (together with its affiliates) may not exercise any portion of its November 2024 Warrant to the extent that the holder would beneficially own more than the Beneficial Ownership Limitation, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation, provided that the Beneficial Ownership Limitation in no event exceeds 19.99%.

Paulson served as the exclusive placement agent for the